Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04126317 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT04126317 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 106 participants.
The verdict
NCT04126317, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of action compared to intravitreal aflibercept injection (hereafter referred to as IAI).
Interventions
- DRUG aflibercept
- DRUG High-dose aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2021-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04126317
The ClinicalTrials.gov registry entry for NCT04126317 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aflibercept is the first listed.
NCT04126317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04126317 about?
NCT04126317 is a clinical study titled "Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration". The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of action compared to intravitreal aflibercept injection (hereafter referred t...
What is the current status of trial NCT04126317?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2019-11-04. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT04126317?
The interventions under investigation include: aflibercept (DRUG), High-dose aflibercept (DRUG).
Who is sponsoring clinical trial NCT04126317?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.